This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background Some markers of inflammation—TNF receptors 1 and 2 (TNFR1 and TNFR2)—are independently associated with progressive CKD, as is a marker of proximal tubule injury, kidney injury molecule 1 (KIM-1). However, whether an episode of hospitalized AKI may cause long-term changes in these biomarkers is unknown.
Methods Among adult participants in the Chronic Renal Insufficiency Cohort (CRIC) study, we identified 198 episodes of hospitalized AKI (defined as peak/nadir inpatient serum creatinine values ≥1.5). For each AKI hospitalization, we found the best matched non-AKI hospitalization (unique patients), using prehospitalization characteristics, including eGFR and urine protein/creatinine ratio. We measured TNFR1, TNFR2, and KIM-1 in banked plasma samples collected at annual CRIC study visits before and after the hospitalization (a median of 7 months before and 5 months after hospitalization).
Results In the AKI and non-AKI groups, we found similar prehospitalization median levels of TNFR1 (1373 pg/ml versus 1371 pg/ml, for AKI and non-AKI, respectively), TNFR2 (47,141 pg/ml versus 46,135 pg/ml, respectively), and KIM-1 (857 pg/ml versus 719 pg/ml, respectively). Compared with matched study participants who did not experience AKI, study participants who did experience AKI had greater increases in TNFR1 (23% versus 10%, P<0.01), TNFR2 (10% versus 3%, P<0.01), and KIM-1 (13% versus −2%, P<0.01).
Conclusions Among patients with CKD, AKI during hospitalization was associated with increases in plasma TNFR1, TNFR2, and KIM-1 several months after their hospitalization. These results highlight a potential mechanism by which AKI may contribute to more rapid loss of kidney function months to years after the acute insult.
- acute renal failure
- chronic kidney disease
- hospitalization
- renal injury
- acute kidney injury
- biomarkers
- plasma
TNF receptors 1 and 2 (TNFR1 and TNFR2) and kidney injury molecule 1 (KIM-1) are strongly associated with CKD progression, even after accounting for patient characteristics including eGFR and proteinuria.1⇓–3 It is unclear why some individuals have higher levels of these biomarkers of inflammation and tubular injury. We hypothesize that biomarker levels may reflect, at least in part, the cumulative effect of prior episodes of AKI.
AKI is associated with the development and progression of CKD,4⇓⇓⇓⇓–9 but the mechanisms by which AKI results in CKD remain unclear.10 In addition to the acute loss of nephron mass than can occur with AKI, some evidence suggests AKI may also lead to faster CKD progression after the initial insult.11,12 Tubules regenerating after necrosis from AKI may fail to differentiate properly, and the resultant cell senescence may potentially cause persistently high signaling activity leading to long-term inflammation and interstitial fibrosis.13 It is unknown whether an episode of AKI may result in long-term increases in these biomarkers strongly predictive of CKD progression.
In this study, we test the hypothesis that among patients with CKD, an episode of hospitalized AKI (hitherto referred to as AKI) is associated with increases in TNFR1, TNFR2, and KIM-1 levels, evident months after the acute insult.
Methods
We studied participants in the Chronic Renal Insufficiency Cohort (CRIC) study, an ongoing multicenter prospective observational cohort study of adults with CKD. Initial recruitment into CRIC started in 2003 and study participants were invited to re-enroll in subsequent 5-year extensions. Additional study participants, who were relatively older and had more preserved eGFR, were enrolled starting in 2013.14 CRIC study participants attended annual in person visits where samples of blood and urine were taken and had mid-year telephone contacts to update medical history (Figure 1). Hospitalizations were ascertained at annual study site visits and mid-year telephone calls to participants or their proxies, along with study personnel review of hospital discharge records collected by active surveillance.15,16 Hospitalizations were classified as cardiovascular or infection-related by the primary International Classification of Diseases, Ninth or Tenth Revision admission code using CCS Software (specific CCS categories shown in Supplemental Appendix 1) developed by the Agency for Healthcare Research and Quality.16 The CRIC study protocol was approved by the institutional review boards of all participating centers and is in accordance with the Declaration of Helsinki. All participants provided written informed consent.
Overview of study design. Selection of study visits and measurements of biomarkers before and after hospitalization.
This study population is drawn from CRIC study participants who were alive and active in the study after July 2013, because it was only after this date that there was systematic capture of inpatient serum creatinine readings available to define presence or absence of AKI. The last hospitalization in our cohort was in December 2019. We adapted the Kidney Disease: Improving Global Outcomes definition to define AKI hospitalizations as those with peak/nadir inpatient serum creatinine values ≥1.5.17,18 To achieve greater separation, we defined non-AKI hospitalizations as those meeting all three of the following criteria: peak/nadir inpatient serum creatinine <1.2, and peak minus nadir inpatient serum creatinine <0.3 mg/dl, and peak inpatient/most recent outpatient study visit serum creatinine <1.5. Hospitalizations that did not meet criteria for AKI or non-AKI were excluded. Hospitalizations after which ESKD developed before the next scheduled annual CRIC study visit postdischarge were also excluded. To enable comparison of biomarker levels before and after hospitalization, we only considered hospital admissions if there were CRIC study visits with both plasma and urine sample collection within 2 years before admission and within 1 year after discharge (Figure 1).
We identified 199 AKI hospitalizations and 1534 non-AKI hospitalizations fulfilling the inclusion/exclusion criteria. We matched each AKI hospitalization to a non-AKI hospitalization (patients could only contribute one hospitalization to the matching) using the following criteria assessed at the prehospitalization annual CRIC study visit in decreasing priority: eGFR from the CRIC specific equation19 (within ±5 ml/min per 1.73 m2), urine protein-creatinine ratio (0–0.3, 0.3–1, or >1 g/g), duration between hospital discharge and next CRIC visit (by 0–30, 30–180, and >180 days), diabetes status (yes/no), age (by 20-year strata), sex (male/female), duration between hospital admission and prior CRIC visit (by 0–30, 30–180, and >180 days). In total, 147 matches met all seven matching criteria, then additional matches were added by sequentially eliminating the next lowest priority criterion. One patient with AKI could not be matched due to missing prehospitalization eGFR. Our final cohort thus included 198 patients with AKI and 198 patients who were non-AKI.
Plasma samples collected at study visits were frozen locally at either −20 or −80°C before being shipped to the central laboratory on dry ice, where they were stored at −80°C until they were thawed for measurement. Plasma biomarkers (TNFR1, TNFR2, and KIM-1) were measured using a multiplex U-PLEX assay on the Meso Scale Discovery platform (Meso Scale Discovery, Gaithersburg, MD) at the Brigham and Women’s Hospital.
Descriptive statistics were presented as proportions, means and standard deviations, or medians and interquartile ranges (IQR). McNemar’s tests for categorical variables and paired t tests and Wilcoxon signed-rank tests (for means and medians, respectively) of continuous variables were used to generate P values for descriptive statistics and for raw biomarker concentrations. TNFR1, KIM-1, and urine protein-creatinine ratio values were right skewed, so values were log-transformed for analysis.
Prehospitalization characteristics
Biomarker levels
Hospitalization and posthospitalization characteristics
To account for possible correlations among matched pairs of patients, the primary analysis comparing changes in biomarkers between AKI and non-AKI groups used a linear mixed-effects model, including the fixed effects of AKI, change between the pre/posthospitalization visits, and their interaction (AKI with change between visits), and random effects of match ID and participant ID: Y = TNFR2 concentration/natural log TNFR1 and KIM-1 concentration = β0 + β1(AKI) + β2(posthospitalization) + β3(AKI*posthospitalization) + random intercept for participant ID + random intercept for matched pair, where β0 is the mean (or mean of the log) of the non-AKI prehospitalization biomarker concentration, and AKI and posthospitalization are binary variables, indicating whether the measurement was measured in a patient with AKI and at the posthospitalization visit. In the primary analysis, no statistical adjustment for confounders was performed because patients had already been matched on important confounders during cohort assembly. However, because some pairs did not meet all seven matching criteria, two sensitivity analyses were performed: (1) repeating the analysis in the subset that did meet all seven matching criteria (n=147 pairs) and (2) further adjustment for matching variables such as age in the entire study cohort (n=198 pairs), because there may be residual differences in, say, age among matched patients with AKI and non-AKI within each 20-year stratum.
Similar mixed-effect models were used to compare changes in eGFR and proteinuria (instead of biomarker concentrations as the outcome).
All analyses were performed using R 4.0.2 (R Core Team [2020] R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org/).
Results
Our final study population included 198 patients with AKI during hospitalization and 198 matched patients without AKI during hospitalization. Patients were well matched on all prehospitalization characteristics, including eGFR (mean 48 ml/min per 1.73 m2), proteinuria, and blood pressure (Table 1), ascertained at the most recent annual CRIC study visit before hospitalization. Prehospitalization plasma concentrations of TNFR1, TNFR2, and KIM-1, measured from banked samples after the cohort was assembled, were also very similar (Table 2, Supplemental Figures 1, 2, and 3).
The duration between the prehospitalization biomarker measurement and hospital admission was about 7 months in both groups (median 221 days, IQR, 138–291 in the AKI group versus 220 days, IQR, 123–283, in the non-AKI group; P=0.06). The period between hospital discharge and the posthospitalization biomarker measurement was also similar at about 5 months (median 161 days, IQR, 93–229, in the AKI group versus 160 days, IQR, 93–247, in the non-AKI group; P=0.20; Table 3). Roughly one quarter of hospitalizations were due to cardiovascular causes in both the AKI and non-AKI groups. A higher percentage of AKI hospitalizations were infection-related (14% in the AKI group versus 8% in the non-AKI group; P=0.12). Two thirds of patients had mild AKI (stage 1). There were no patients with AKI who required dialysis.
Comparing pre- and posthospitalization measurements, AKI was associated with significantly greater increases in the median concentrations of all three plasma biomarkers (Table 2). TNFR1 increased by a median 23% in the AKI group and by 10% in the non-AKI group (P<0.01). TNFR2 increased by a median 10% in the AKI group and by 3% in the non-AKI group (P<0.01). KIM-1 increased by a median 13% in the AKI group, but decreased by 2% in the non-AKI group (P<0.01) (Table 2). In the mixed-effects model accounting for matched pairs, all differences remained statistically significant (P=0.01, P=0.003, P=0.002 for TNFR1, TNFR2, and KIM-1, respectively). Results were substantively unchanged in sensitivity analyses accounting for imperfect matching (Supplemental Table 1).
eGFR decreased from prehospitalization to posthospitalization in the AKI group, from a mean of 48 ml/min per 1.73 m2 to 44 ml/min per 1.73 m2 compared with 48 ml/min per 1.73 m2 to 47 ml/min per 1.73 m2 in the non-AKI group (P=0.008 for difference in the mixed-effects model accounting for matched pairs). The mean urine PCR went from 0.24 g/g to 0.31 g/g in the AKI group versus 0.26 g/g to 0.27 g/g in the non-AKI group (P=0.29).
Discussion
We found that among patients with pre-existing CKD, AKI was associated with long-term increases in plasma TNFR1, TNFR2, and KIM-1, despite similar prehospitalization levels. These elevations were found on post-AKI measurements a median of 5 months after hospital discharge (median 1 year between the prehospitalization and posthospitalization measurements), which demonstrates that AKI-associated changes in plasma biomarkers are not limited to the perihospitalization period. These long-term changes in biomarkers related to tubular injury and inflammation may help provide insight into the pathophysiology connecting AKI and subsequent further loss of kidney function.
TNFR1, TNFR2, and KIM-1 are biomarkers strongly associated with kidney disease progression.1⇓–3,20 For example, in samples from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and the Veterans Administration NEPHROpathy iN Diabetes (NEPHRON-D) studies, plasma TNFR1, TNFR2, and KIM-1 independently predicted progression of diabetic kidney disease.21 Another study that evaluated a panel of 297 plasma biomarkers found that >75% of the predictive information provided by the panel came from KIM-1 and CD27 (another marker of inflammation in the TNF receptor superfamily).22 Plasma KIM-1 and TNFR1 have both been shown to be associated with progressive kidney disease in type 1 diabetes despite adjustments for eGFR, blood pressure, A1c, and urinary albumin.23 Similar results have been seen in the cardiac surgery population3 and other populations.21,24
Some investigators have suggested these biomarkers are not only indicators of risk, but actually mechanistically important in the pathophysiological pathway.25 TNFR1 and TNFR2 are both cell membrane receptors for TNF-α that are shed into the plasma after cleavage by a metalloproteinase.26 TNFR1 is expressed in glomeruli and the peritubular endothelium, whereas TNFR2 is usually only expressed in areas of renal injury. Both reflect activation of the proinflammatory TNF pathway. KIM-1, a transmembrane protein involved in immune regulation and the inflammatory response, is upregulated in the proximal tubule after acute tubular injury.25,27 AKI with resultant tubular cell injury and regeneration may upregulate these molecules as part of healthy repair processes.10,13 However, the persistence of elevated levels of these signaling molecules months after AKI suggests some of the inflammatory and fibrotic processes necessary for repair may not fully return to baseline, and then may contribute to self-sustaining tubulointerstitial fibrosis. The elevated markers may be indicators of ongoing inflammatory processes and chronic proximal tubule injury, or they may be causally related to the progressive decline in kidney function. Supporting this latter possibility, in a murine model, experimentally increased KIM-1 expression caused kidney inflammation and fibrosis in a murine model.28 In another murine model, TNFR2-deficient mice had less-severe renal dysfunction after cisplatin-induced AKI.29 In human kidney biopsies, TNFR1 and TNFR2 levels have been associated with histopathologic lesions of glomerular and tubulointerstitial inflammation.30 Thus, these biomarkers may be worthwhile targets for therapeutics aimed at reducing CKD progression.31,32
Among patients with CKD, there is large between-person variability in levels of TNFR1, TNFR2, and KIM-1, which is not readily explained by observed variability in concurrent levels of eGFR, albuminuria, or other patient-level characteristics. With the greater appreciation in the past 10–15 years that AKI and CKD have a closer relationship than previously realized, and the natural history of CKD is punctuated by episodes of AKI, we hypothesized that prior episodes of AKI may contribute to differences in plasma levels of TNFR1, TNFR2, and KIM-1 in patients with CKD. Apart from the results of this study, little is known about changes in TNFR1 and TNFR2 levels after AKI. Higher levels of TNFR1 and TNFR2 measured at a single timepoint in patients who are critically ill have been associated with AKI and mortality,33,34 but levels were not measured before and after AKI. We are not aware of any prior studies evaluating changes in human plasma TNFR1 and TNFR2 levels before and after AKI, although increases have been reported in murine models of AKI from cisplatin nephrotoxicity and ischemic-reperfusion injury.26,29,35 Plasma levels of KIM-1 are known to rise after AKI, but most studies have measured biomarkers only in the short term (days after AKI). Plasma KIM-1 levels rose after postcardiac surgery AKI in two studies with pre- and postsurgery samples,3,36 but samples were only collected up to 5 days after surgery. More is known about long-term elevation of urinary KIM-1. A study of urinary KIM-1 levels showed that acute elevations in urinary KIM-1 persisted for 7 years after AKI in a pediatric cardiac surgery population.37 This study concurs with our result that AKI is associated with increases in KIM-1 that persist beyond the peri-AKI period.
Although caution must be exercised in the interpretation of absolute biomarker levels (because these may vary by assay platform), the absolute rise in KIM-1 we observed in the AKI group (59 pg/ml) is similar in magnitude to the difference between patients who developed early diabetic kidney disease and controls in ACCORD (75 pg/ml).21 In a study of patients with diabetes without CKD, the difference between the top and bottom tertiles of plasma KIM-1 was small (31 pg/ml), but was still associated with the development of CKD.23 For TNFR1, we saw an increase of 247 pg/ml in the AKI group. By comparison, in the Multi-Ethnic Study of Atherosclerosis (MESA) general population cohort, each standard deviation higher concentration of TNFR1 (406 pg/ml) was associated with a 43% higher hazard for CKD progression.24 The difference between patients and controls in ACCORD was about 500 pg/ml.21 For TNFR2, we saw an increase of 4697 pg/ml in the AKI group. The differences between patients/controls in ACCORD/NEPHRON-D were 1000–3000 pg/ml.21 Even if the effect on biomarker levels of a single episode of the mostly mild AKI seen here (66% stage 1 AKI) is small, repeated episodes of AKI could have a cumulative effect.
We found eGFR was lower at the posthospitalization visit (median 161 days after discharge) in patients with AKI. Thus, another possible explanation for the biomarker increases we observed is that decreased GFR results in elevated concentrations of these molecules because of reduced clearance. We believe this is less likely (although impossible to rule out) because these molecules are rather large (90 kDa soluble portion for KIM-1,27 55 kDa for TNFR1,38 and 80 kDa for TNFR239) and thus would not be expected to be filtered at the glomerulus. The fact that plasma biomarker concentrations predict future CKD progression despite adjustment for eGFR level21⇓⇓–24 also suggests that biomarker concentrations are not determined solely by glomerular clearance. Finally, the murine models mentioned above28,29 suggest these biomarkers may directly cause GFR to fall (rather than a falling GFR causing biomarkers to rise).
Strengths of our study include the use of pre-AKI biomarker levels, which are often not available, and the long-term follow-up of patients with repeat biomarker measurements several months after hospital discharge. CRIC is an ideal data source for this type of analysis because it has regular annual study visits with plasma collection and detailed serum creatinine information from intervening hospitalizations. Another strength of these data is the use of strict definitions for both AKI and non-AKI on the basis of laboratory information. With these definitions, patients who were borderline, and were not clearly AKI or non-AKI, were excluded to avoid misclassification. Our data were not restricted to a particular type of hospital admission or cause of AKI (e.g., postcardiac surgery), as has been the case for other studies looking at plasma AKI biomarkers,3,36 because surgery is one of the few causes of AKI that is predictable, and thus allows sample collection before and after AKI.
Our study also has some limitations. We cannot exclude the possibility that some confounding factor associated with AKI but not accounted for here (e.g., critical illness requiring intensive care unit admission) may be the cause of the elevated biomarker levels. We also do not have information on the AKI etiology (although there is no accepted method for adjudicating AKI etiology40) or on the clinical context in which AKI occurred (e.g., ischemic versus nephrotoxic). Numerous patients had additional hospitalizations in between the two biomarker measurements (median 1 hospitalization with IQR, 0–2 hospitalizations in both the AKI and non-AKI groups). But only 7% of additional hospitalizations included an AKI episode in the AKI group, compared with 3% in the non-AKI group, so misclassification appears unlikely to be an important source of bias. The definition of AKI we used relies entirely on changes in creatinine and does not capture changes in urinary volume and proteomics. It may therefore be nonspecific for intrinsic kidney damage (versus other causes of creatinine rise such as volume depletion).41 This effect would also bias toward the null. Our cohort included only patients with pre-existing CKD, so these results may not be generalizable to populations without CKD.
In summary, hospitalized AKI was associated with long-term increases in plasma TNFR1, TNFR2, and KIM-1 concentrations several months after hospitalization. Additional studies to better characterize long-term trends in biomarkers of tubular injury and inflammation after AKI, coupled with studies to explore the direct effects of elevations in these biomarkers, may provide further insight into the pathophysiology by which AKI leads to progressive CKD.
Disclosures
A. Go reports employment with Kaiser Permanente Northern California; and reports receiving research funding from Amarin Pharmaceuticals, Bristol Meyers-Squibb, CSL Behring, Esperion Pharmaceuticals, iRhythm Technologies, Janssen Research and Development, and Novartis. A. Srivastava reports being a consultant for CVS Caremark, and Tate & Latham (Medicolegal consulting); reports receiving honoraria from AstraZeneca, Bayer, and Horizon Therapeutics; and reports receiving speakers bureau from AstraZeneca. C. Hsu reports consulting for legal cases involving acute or CKD, and consults on an ad hoc basis for companies regarding kidney disease; reports receiving research funding from Satellite Healthcare; and reports receiving honoraria from Satellite Healthcare and royalties from UpToDate. C. Parikh reports being a consultant for Genfit Biopharmaceutical Company; reports having an ownership interest in Renaltix AI; reports receiving research funding from the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); and reports having an advisory or leadership role with Genfit Biopharmaceutical Company and Renalytix. J. Bonventre reports consultancy agreements with Aditum, Caladrius, Citrine, Janssen, MediBeacon, Praxis, and Sarepta; reports having an ownership interest in Autonomous Medical Devices, Coegin, Goldfinch, Goldilocks, Medibeacon, Pacific Biosciences, Theravance, Sentien, and Verinano; reports having patents for Kim-1 patents and kidney organoid patents assigned to Mass General Brigham; and reports having an advisory or leadership role with Advisory Board of Northwest Kidney Center, Angion, CPath AKI Biomarker Initiative, Editor Seminars in Nephrology, Kidney Health Initiative AKI Biomarker Initiative, and Wearable Artificial Organs. D. Cohen reports being a consultant for Medtronic, Metavention, Novartis, and Recor; reports having an ownership interest with Incyte and Kura (spouse); reports receiving research funding from CRIC study and Medtronic; reports receiving honoraria from Medtronic, Metavention, Novartis, Recor; reports having patents or royalties Incyte (spouse); and reports having an advisory or leadership role with Kura Oncology (spouse). I. Mccoy reports receiving research funding from Satellite Healthcare Inc. (nonprofit). J. Hsu reports having an advisory or leadership role with the American Journal of Kidney Diseases (AJKD), Statistics/Epidemiology Editor, PLOS ONE, Statistical Advisory Board. K. Liu reports being a consultant for AM Pharma, Biomerieux, BOA Medical, and Seastar Medical; reports having an ownership interest Amgen (hold stock only); reports having an advisory or leadership role with American Journal of Respiratory and Critical Care Medicine, AJKD, and CJASN Editorial Boards, the American Thoracic Society, and the National Kidney Foundation Scientific Advisory Board; and other reports interests or relationships with UpToDate. P. Rao reports receiving honoraria from AstraZeneca; and reports having an advisory or leadership role with AstraZeneca Nephrology Fellowship Advisory Board, GSK scientific advisory board, and the Renal Research Institute. All remaining authors have nothing to disclose.
Funding
This work was supported by the National Institutes of Health (NIH) grants R01DK114014, R01DK072381 and R37DK39773, and K24DK92291. Funding for the CRIC study was obtained under a cooperative agreement from the NIDDK (grants U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, and U24DK060990) and by Clinical and Translational Science Awards to the Perelman School of Medicine at the University of Pennsylvania (NIH/National Center for Advancing Translational Sciences (NCATS) UL1TR000003), Johns Hopkins University (UL1TR000424), University of Maryland General Clinical Research grant M01RR16500, Clinical and Translational Science Collaborative of Cleveland (UL1TR000439) from the NCATS component of the NIH and the NIH Roadmap for Medical Research, Michigan Institute for Clinical and Health Research (UL1TR000433), University of Illinois at Chicago (UL1RR029879), Tulane Center of Biomedical Research Excellence for Clinical and Translational Research in Cardiometabolic Diseases (P20GM109036), Kaiser Permanente (NIH/National Center for Research Resources University of California, San Francisco Clinical and Translational Science Institute grant UL1RR024131), and the Department of Internal Medicine, University of New Mexico School of Medicine (NM R01DK119199).
Acknowledgments
A portion of this work was presented at the American Society of Nephrology Annual Meeting in San Diego, CA, November 4, 2021 (PO0417).
Author Contributions
Dr. Chi-yuan Hsu, Dr. Ian E. McCoy, Dr. Jesse Y. Hsu, Dr. Joseph V. Bonventre, Dr. Chirag R. Parikh, Dr. Alan S. Go, Dr. Jiang He, and Dr. Panduranga Rao designed the study; Dr. Chi-yuan Hsu, Dr. Ian E. McCoy, Dr. Jesse Y. Hsu, Dr. Joseph V. Bonventre, Dr. Chirag R. Parikh, Dr. Alan S. Go, Dr. Kathleen D. Liu, Dr. Ana Ricardo, Dr. Debbie L. Cohen, Dr. Jiang He, Dr. Jing Chen, and Dr. Panduranga Rao acquired the data; Dr. Joseph V. Bonventre carried out assays; Dr. Jesse Y. Hsu performed the statistical analysis; Dr. Ian E. McCoy and Dr. Chi-yuan Hsu drafted the paper; and all authors analyzed and interpreted the data, revised the paper, and approved the final version of the manuscript.
Data Sharing Statement
Observational Data is available in the NIDDK Repository (https://repository.niddk.nih.gov/home/). Additional information is available upon request.
Supplemental Material
This article contains the following supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2021111453/-/DCSupplemental.
Supplemental Appendix 1. CCS categories used to classify hospitalizations.
Supplemental Table 1. Sensitivity analyses.
Supplemental Figure 1. Box and whisker plot of plasma TNFR1 concentrations.
Supplemental Figure 2. Box and whisker plot of plasma TNFR2 concentrations.
Supplemental Figure 3. Box and whisker plot of plasma KIM-1 concentrations.
Footnotes
Published online ahead of print. Publication date available at www.jasn.org.
- Copyright © 2022 by the American Society of Nephrology
References
If you are:
- an ASN member, select the "ASN Member" login button.
- an individual subscriber, login with you User Name and Password.
- an Institutional user, select the Institution option where you will be presented with a list of Shibboleth federations. If you do not see your federation, contact publications@asn-online.org.
ASN MEMBER LOGIN
Log in using your username and password
Log in through your institution
Purchase access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$34.00
In order to get access to the article, you must have an account. If you have an account, enter your user name and password into the boxes above. If you do not have an account, follow the instructions below to create one. Once you have purchased the article, you will have access to it for 24 hours.
Steps for Creating an Account:
Click the "Purchase Access" button. The page will redisplay with the following message at the top of the screen. In the message, click to create an account.
When you create the account, you will be asked to register a user name, email address and you will need to create a password that is at least eight characters in length. You do not need an ASN Member number to complete the form. As you move through the registration page, you will have to verify you are a person by completing a Captcha request. Lastly, your first and last name will be required.
Once your information is successfully saved, the system will redisplay the home page of the journal. From there, navigate back to the article to purchase. Select the article and at the bottom of the page, use the credentials you just created to login. The article will be added to your shopping cart. You can continue to navigate across JASN and CJASN adding to your cart from both journals. When you are ready to complete your purchse, select the Shopping Cart from the upper right hand corner of the page and follow the onscreen instructions.
In this issue
Jump to section
More in this TOC Section
Clinical Research
Cited By...
- No citing articles found.